Aldeyra posts FY2022 net loss $62.0M, cash $174.3M; two NDAs under FDA review with PDUFA dates June and Nov 2023

Aldeyra Therapeutics, Inc.

Net loss $62.0M ($1.06/share) vs $57.8M ($1.07/share) in 2021; R&D $47.3M, G&A $15.4M.
Cash $174.3M at Dec 31, 2022; runway into H2 2024, covering launch preparations if approved.
FDA Priority Review for ADX-2191 (vitreoretinal lymphoma) with PDUFA June 21, 2023; no filing issues identified.
FDA accepted NDA for reproxalap (dry eye disease) with PDUFA Nov 23, 2023; no advisory committee planned.
Upcoming: Phase 3 INVIGORATE-2 allergic conjunctivitis, Phase 2 ADX-2191 RP, Phase 2 ADX-629 cough results expected H1 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.